Working… Menu

Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01004120
Recruitment Status : Completed
First Posted : October 29, 2009
Last Update Posted : March 25, 2016
University of Reading
Information provided by (Responsible Party):

Brief Summary:
The traditional risk factors for obesity are inappropriate diet, lack of exercise and genetic factors. However, recent observations have involved gut microbiota profiles as having an additional influence. In this case, there exists the possibility to modulate this through diet. Research has shown that the gut microbiota of both obese humans and mouse models of obesity is altered towards less beneficial one compared to lean counterparts. This raises the possibility of modulating the gut microbiota as a novel strategy in tackling the epidemic of obesity and diabetes sweeping the developed world. In addition, a more direct effect of high-fat induced disruption of the intestinal microbiota has also been seen with a murine model. Elevated circulating levels of lipopolysaccharide (LPS) a major building block and antigen of Gram-negative bacteria, was shown to generate a low grade chronic inflammation, termed metabolic endotoxemia, which then onsets insulin resistance. High-fat diets were shown to disrupt the Gram-negative intestinal populations of these animals, liberating LPS. The effects of prebiotics on the microbiota or metabolic syndrome (combination of disorders that increase the risk of developing cardiovascular disease and diabetes) in overweight adults have not been investigated thus far. The investigators therefore propose to investigate the effect of galactooligosaccharide (GOS) on the faecal microbiota and metabolic syndrome risk factors in overweight adults in a double-blind, randomised, placebo controlled, cross-over trial.

Condition or disease Intervention/treatment Phase
Metabolic Syndrome X Dietary Supplement: Bimuno Dietary Supplement: Maltodextrin Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Double-blind, Placebo Controlled, Randomised, Cross-over Study to Determine the Effect of a Prebiotic Galactooligosaccharide on Microbiota and Metabolic Syndrome Risk Factors in Overweight Adults
Study Start Date : October 2009
Actual Primary Completion Date : December 2011
Actual Study Completion Date : December 2012

Arm Intervention/treatment
Placebo Comparator: MDn Dietary Supplement: Maltodextrin
5.5g daily intake
Other Name: Dexrins

Active Comparator: B-GOS Dietary Supplement: Bimuno
5.5g daily intake
Other Name: Galactooligosaccharide

Primary Outcome Measures :
  1. Faecal microbiota changes enumerated by Fluorescent In Situ Hybridisation and qualitatively assessed by Denaturing Gradient Gel Electrophoresis. [ Time Frame: 3 months ]
  2. Lipid profile (total, LDL and HDL cholesterol, triglycerides and non-esterified fatty acids) [ Time Frame: 3 months ]
  3. Inflammatory/thrombotic biomarkers (including C-reactive protein, TNF-a, IL6, IL-8, IL-10, sCD40L, sP-selectin, t-PA) [ Time Frame: 3 months ]

Secondary Outcome Measures :
  1. Insulin resistance derived from fasted measures of glucose and insulin ratio [ Time Frame: 3 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • 18-65y
  • BMI >25 kg/m2

Exclusion Criteria:

  • Suffered from a myocardial infarction/stroke or cancer in the past 12 months
  • Diabetic or suffering from endocrine disorders
  • Suffer from renal or bowel disease/gut disorder or have a history of cholestatic jaundice or pancreatitis
  • Requirements to take long-term medication for hyperlipidaemia, hypertension, inflammation or hypercoagulation
  • History of alcohol or drug abuse
  • Planning or on a weight reducing regime
  • Taking antioxidant (or phytochemical), probiotic or prebiotics supplements
  • Pregnant or lactating women or those planning pregnancy in the next 6 months or of child-bearing age who are not using contraception
  • Use of antibiotics within the previous 1 month
  • Anemic
  • Smoker

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01004120

Layout table for location information
United Kingdom
School of Chemistry, Food Biosciences and Pharmacy, The University of Reading
Reading, Berkshire, United Kingdom, RG6 6AU
Sponsors and Collaborators
University of Reading
Layout table for investigator information
Principal Investigator: Jelena Vulevic, PhD The University of Reading
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Clasado Identifier: NCT01004120    
Other Study ID Numbers: COMSE
First Posted: October 29, 2009    Key Record Dates
Last Update Posted: March 25, 2016
Last Verified: March 2016
Additional relevant MeSH terms:
Layout table for MeSH terms
Metabolic Syndrome
Pathologic Processes
Body Weight
Insulin Resistance
Glucose Metabolism Disorders
Metabolic Diseases